Search

Displaying results 5611 - 5620 of 10000 in total
  1. Drug

    VTP-201227

    go.drugbank.com/drugs/DB05652
    Experimental

    VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications. … It is being developed by Vitae Pharmaceuticals.

  2. Drug

    BIIB015

    go.drugbank.com/drugs/DB06304
    Investigational

    BIIB015 is a humanized, IgG1 [immunoglobulin G 1], DM4-Conjugated, anti-cripto, monoclonal antibody. It has been investigated for the treatment of subjects with relapsed or refractory solid tumours.

  3. Drug

    Basic Fibroblast Growth Factor

    go.drugbank.com/drugs/DB14131
    Investigational

    Although it is not approved for use in Canada or the USA, bFGF is currently undergoing investigation in a number of clinical trials. … Basic Fibroblast Growth Factor (bFGF) is a single-chain polypeptide growth factor that plays a significant role in the process of wound healing and is a potent inducer of physiologic angiogenesis.

  4. Drug

    Otenabant

    go.drugbank.com/drugs/DB11745
    Investigational

    Otenabant has been investigated for the treatment of Obesity.

  5. Drug

    Bethanidine

    go.drugbank.com/drugs/DB00217
    Approved

    A guanidinium antihypertensive agent that acts by blocking adrenergic transmission.

    Synonyms: N,N'-dimethyl-N''-(phenylmethyl)-guanidine
  6. Drug

    Serinus canaria feather

    go.drugbank.com/drugs/DB10857
    Approved

    Canary feather is used in allergenic testing.

  7. Drug

    Roquinimex

    go.drugbank.com/drugs/DB11366
    Experimental

    Roquinimex is a derivative of quinoline that presents immunostimulant properties. Its effects are suggested to increase the activity of NK cells and macrophage cytotoxicity. … Additionally, roquinimex is known to inhibit angiogenesis and to decrease the synthesis of TNF alpha.

  8. Drug

    IC41

    go.drugbank.com/drugs/DB05776
    Investigational

    IC41 is a therapeutic peptide vaccine. It is being devloped by Intercell AG for the treatment of hepatitis C. … The vaccine consists of five synthetic peptides (IPEP83, 84, 87, 89,1426) harboring HCV CD4 and CD8 T-cell epitopes and the synthetic adjuvant poly-L-arginine.

  9. Drug

    Clobutinol

    go.drugbank.com/drugs/DB09004
    ApprovedWithdrawn

    Clobutinol is a cough suppressant that is withdrawn from the US and EU markets. Clobutinol may prolong the QT interval. In 2007, Clobutinol was determined to cause cardiac arrhythmia in some patients.

  10. Drug

    Prolease-r-hFSH

    go.drugbank.com/drugs/DB05826
    Experimental

    It provides patients with long term therapeutic benefit from a single administration rather than multiple injections. … Prolease-r-hFSH is a recombinant human follicle stimulating hormone (r-hFSH) with Alkermes' ProLease injectable sustained release drug delivery technology.